Abstract
The increasing demand for new pharmaceuticals faces critical barriers to overcome. These barriers pertain to efficacy, safety, regulatory compliance, and cost-effectiveness. Despite progressive investment by companies in research, studies show that in the United States, only 0.1% of new drugs in development advance to clinical trials. Among these, only 10.0% are approved. In this context,…